Biodiversity | ~5 min read

Why biodiversity matters for health - and investment

Biodiversity loss is increasingly a health crisis – and one with real economic consequences. From food systems to infectious disease risk, the links are becoming harder to ignore.

On the International Day for Biological Diversity, understanding how these dynamics feed through to investments is more urgent than ever.

As biodiversity declines, the risks to human health – and the economy – are rising. The One Health concept provides a framework to understand these risks. Developed in the early 2000s and backed by organisations such as the World Health Organization, it highlights the deep interconnections between human, animal and environmental health – and the need for coordinated action across them. One Health promotes cross-sector collaboration to strengthen food and health systems and tackle challenges such as infectious diseases and antimicrobial resistance.

Biodiversity disruption

Health has typically been poorly integrated into environmental policies, but in 2022 the Global Action Plan on Biodiversity and Health – agreed by 195 countries and the EU – recognised biodiversity as foundational for human health, calling for a stronger One Health approach.1

Degraded ecosystems and heightened disease risks are undermining food systems and eroding essential ecosystem services, contributing to an estimated 15 million deaths and USD 4 trillion in economic losses since 2023.2 Microplastic pollution is one example, disrupting ecosystems and entering the food chain and threatening food safety, health and livelihoods.

Connectivity is key

A functioning One Health framework requires structural changes across fragmented health, environmental and animal systems. Barriers exist, including limited data sharing, fragmented surveillance systems and weak coordination. Effective prevention and policy alignment are further constrained by poor understanding of disease spread from animals to humans (known as zoonotic spillovers), often driven by land-use change, wildlife trade and urbanisation. The current outbreaks of Hantavirus in Europe and Ebola in West Africa are stark reminders of this.

We see an urgent need for standardised risk assessment frameworks and practical tools.

Investment implications

One Health provides a strategic framework to identify and mitigate systemic risks, helping guide capital towards resilience. Its greatest value lies in prevention, which can be difficult to quantify. The World Bank estimates potential global benefits from a unified approach of USD 37 billion annually, compared with prevention costs of USD 3.4 billion.3

This is an opportunity to strengthen global resilience and support more equitable economic systems. We are committed to integrating biodiversity into our investment processes to support long-term value creation.

Read more about biodiversity loss: Nature risk is now financial risk | AllianzGI

 

1 UN Environment Programme, Convention on Biological Diversity, October 2024
2  World Health Organization, One Health factsheet, May 2026
3 The World Bank Group, One Health

Investing involves risk. The value of an investment and the income from it may fall as well as rise and investors might not get back the full amount invested. Past performance does not predict future returns. If the currency in which the past performance is displayed differs from the currency of the country in which the investor resides, then the investor should be aware that due to the exchange rate fluctuations the performance shown may be higher or lower if converted into the investor’s local currency. This is for information only and not to be construed as a solicitation or an invitation to make an offer to buy or sell any securities. The views and opinions expressed herein, which are subject to change without notice, are those of the issuer or its affiliated companies at the time of publication. The data used is derived from various sources and assumed to be accurate and reliable at the time of publication. but it has not been independently verified; its accuracy or completeness is not guaranteed and no liability is assumed for any direct or consequential losses arising from its use, unless caused by gross negligence or willful misconduct. The duplication, publication, extraction or transmission of the contents, irrespective of the form, is not permitted, except for the case of explicit permission by Allianz Global Investors. This material has not been reviewed by any regulatory authorities.

This document is being distributed by the following Allianz Global Investors companies: In Australia, this material is presented by Allianz Global Investors Asia Pacific Limited (“AllianzGI AP”) and is intended for the use of investment consultants and other institutional/professional investors only, and is not directed to the public or individual retail investors. AllianzGI AP is not licensed to provide financial services to retail clients in Australia. AllianzGI AP is exempt from the requirement to hold an Australian Foreign Financial Service License under the Corporations Act 2001 (Cth) pursuant to ASIC Class Order (CO 03/1103) with respect to the provision of financial services to wholesale clients only. AllianzGI AP is licensed and regulated by Hong Kong Securities and Futures Commission under Hong Kong laws, which differ from Australian laws; in the European Union, by Allianz Global Investors GmbH, an investment company in Germany, authorized by the German Bundesanstalt für Finanzdienstleistungs-aufsicht (BaFin) and is authorized and regulated in South Africa by the Financial Sector Conduct Authority; in the UK, by Allianz Global Investors (UK) Ltd. company number 11516839, authorised and regulated by the Financial Conduct Authority (FCA); in Switzerland, by Allianz Global Investors (Schweiz) AG, authorised by the Swiss financial markets regulator (FINMA); in HK, by Allianz Global Investors Asia Pacific Ltd., licensed by the Hong Kong Securities and Futures Commission; in Singapore, by Allianz Global Investors Singapore Ltd., regulated by the Monetary Authority of Singapore [Company Registration No. 199907169Z]; in Japan, by Allianz Global Investors Japan Co., Ltd., registered in Japan as a Financial Instruments Business Operator [Registered No. The Director of Kanto Local Finance Bureau (Financial Instruments Business Operator), No. 424], Member of Japan Investment Advisers Association, the Investment Trust Association, Japan and Type II Financial Instruments Firms Association; In mainland China, it is for Qualified Domestic Institutional Investors scheme pursuant to applicable rules and regulations and is for information purpose only. in Taiwan, by Allianz Global Investors Taiwan Ltd., licensed by Financial Supervisory Commission in Taiwan; and in Indonesia, by PT. Allianz Global Investors Asset Management Indonesia licensed by Indonesia Financial Services Authority (OJK) and in the Abu Dhabi Global Market by Allianz Global Investors Middle East Limited, which is authorised and regulated by the ADGM Financial Services Regulatory Authority.

Admaster 5508093

Allianz Global Investors

You are leaving this website and being re-directed to the below website. This does not imply any approval or endorsement of the information by Allianz Global Investors Asia Pacific Limited contained in the redirected website nor does Allianz Global Investors Asia Pacific Limited accept any responsibility or liability in connection with this hyperlink and the information contained herein. Please keep in mind that the redirected website may contain funds and strategies not authorized for offering to the public in your jurisdiction. Besides, please also take note on the redirected website’s terms and conditions, privacy and security policies, or other legal information. By clicking “Continue”, you confirm you acknowledge the details mentioned above and would like to continue accessing the redirected website. Please click “Stay here” if you have any concerns.